Moreover, due to high molecular heterogeneity of the GBM in patients, nSMase1 might be a useful guide to establish GBM prognosis and precision treatment strategies in patients with mutant p53 which could benefit from the use of 1α,25(OH)2VD3 as a therapeutic adjuvant. Here, TP53 is linked to glioblastoma.